Earlier today, Vertex Pharmaceuticals, the company behind VX-809, announced that they will initiate the next phases of the trials for VX-809. They are moving forward with Phase 3 for homozygous DF508 patients, and a shorter Phase 2 trial for heterozygous DF508 patients. We're getting 1 step closer! I'm remaining cautiously optimistic that the study results will continue to be favorable, and that we can start getting the drugs into the hands of part of the DF508 population as early as next year.
You can read the information from Vertex here.